Welcome to our dedicated page for Bio-Techne news (Ticker: TECH), a resource for investors and traders seeking the latest updates and insights on Bio-Techne stock.
Overview
Bio-Techne Corporation (NASDAQ: TECH) is a globally recognized life sciences company offering innovative bioactive reagents, consumables, and instruments. Its extensive portfolio supports a broad spectrum of applications in clinical diagnostics, drug discovery, and biological research. Using advanced immunoassays, spatial biology tools, and protein analysis reagents, Bio-Techne equips scientists with the essential resources to investigate complex biological processes and disease mechanisms.
Core Business Areas
Bio-Techne organizes its operations into two primary segments:
- Protein Sciences: This segment supplies specialized reagents such as antibodies, cytokines, and growth factors, along with analytical instruments, that serve as critical tools for protein analysis and cell biology. These products are employed in both basic and advanced research settings, reflecting a strong commitment to scientific precision and reproducibility.
- Diagnostics and Spatial Biology: Focused on clinical diagnostic solutions, this segment offers molecular tests, diagnostic reagents, and spatial biology products. These tools facilitate reliable clinical assays, supporting translational research and precision medicine through enhanced imaging and biomarker analysis.
Global Reach and Market Position
Based in Minnesota, Bio-Techne has established a significant market presence globally. Its products are widely used in North America, Europe, the Middle East, Africa, the UK, and Asia-Pacific. This international footprint, combined with a deep and diverse product catalog, positions the company as a key contributor to high-quality scientific research and diagnostic testing worldwide.
Innovation and Strategic Collaborations
Innovation is at the core of Bio-Techne’s operations. The company invests heavily in research and development to integrate emerging technologies, such as AI-assisted protein design and automated spatial biology platforms, into its product lines. Strategic collaborations with academic institutions, industry partners, and regional distributors further enhance its capabilities and propel breakthrough innovations. These partnerships not only accelerate product development but also ensure that the tools provided are seamlessly integrated into existing research and clinical workflows.
Product Portfolio and Revenue Streams
Bio-Techne offers an extensive inventory of bioactive reagents and research tools. Its products cater to a wide array of scientific needs ranging from basic research to clinical diagnostics. By providing both Research Use Only (RUO) and Good Manufacturing Practice (GMP) grade products, the company meets the rigorous demands of biotechnology, pharmaceutical, and academic sectors. Its revenue is generated through direct sales, licensing agreements, and strategic distribution deals, all of which underscore the company’s role as a pivotal enabler of scientific exploration.
Competitive Landscape
In a crowded marketplace, Bio-Techne stands out by leveraging its robust product portfolio, cutting-edge technological integration, and a proven track record of intellectual property innovation. While competitors offer similar life sciences tools, Bio-Techne differentiates itself with high-quality, reliable products and ongoing legal protections that reinforce its investment in research and development.
Customer Focus and Operational Excellence
The company prioritizes customer success by delivering reproducible and high-performance research tools that enhance scientific discovery. It regularly engages with the scientific community through educational workshops, technical discussions, and industry events, ensuring its customers remain at the forefront of innovation. This commitment to operational excellence has solidified Bio-Techne’s reputation as a trusted partner in both research and clinical diagnostic communities.
Conclusion
Overall, Bio-Techne Corporation is a cornerstone in the life sciences industry. Through its dual focus on Protein Sciences and Diagnostics & Spatial Biology, the company provides essential tools and innovative solutions that empower researchers and clinicians alike. Its global reach, strategic collaborations, and continuous push for technological advancement highlight its pivotal role in advancing biomedical research and clinical diagnostics.
Bio-Techne Corporation (NASDAQ: TECH) announced the launch of its RNA-Protein Co-Detection Assays, enhancing the RNAscope™ technology. This innovation allows simultaneous examination of gene expression and secreted proteins in intact cells and tissues, addressing the challenges of traditional ISH and IHC methods. The assays utilize patented RNAscope and BaseScope™ technologies for improved specificity and sensitivity. Bio-Techne aims to combine its extensive antibody portfolio with RNAscope technology, facilitating advanced research in infectious diseases and cancer biology.
Bio-Techne Corporation (NASDAQ: TECH) announced the rebranding of its B-MoGen Biotechnologies portfolio to R&D Systems on September 21, 2020. This change includes the retirement of the B-MoGen website, with all products and services now accessible through R&D Systems' site. President Dave Eansor highlighted that this consolidation aims to enhance service offerings for cell and gene therapy customers, providing value-added services alongside high-quality products. More details on the TcBuster gene transfer system can be found on their new site.
Bio-Techne Corporation (NASDAQ: TECH) and QIAGEN N.V. have expanded their non-exclusive partnership focusing on exosome technology. The agreement allows QIAGEN to use Bio-Techne's exosome technology for developing companion in vitro diagnostic products. This partnership will promote the technology among biopharma partners for an initial 24 months, potentially extendable. Furthermore, both companies are extending their exclusive collaboration for product development through Exosome Diagnostics until 2028, enhancing marketing efforts around exosome technologies.
Bio-Techne Corporation (NASDAQ: TECH) has partnered with baseball legend Cal Ripken Jr. to promote prostate cancer awareness, coinciding with Prostate Cancer Awareness Month. Ripken, who was treated for prostate cancer, aims to educate men about the ExoDx™ Prostate test, pivotal in his own health journey. The test assists in biopsy decisions and has gained Medicare coverage, as well as recognition from the VA Healthcare system and NCCN guidelines. Bio-Techne's EPI test is now available with an at-home collection kit, enhancing accessibility for patients.
Bio-Techne Corporation (NASDAQ: TECH) will be presenting at the 2020 Wells Fargo Virtual Healthcare Conference on September 9, 2020, at 11:20 a.m. EDT. The presentation will be led by Chuck Kummeth, the company's CEO. Interested parties can access the live webcast via Bio-Techne's Investor Relations website. In fiscal 2020, Bio-Techne generated approximately $739 million in net sales and is known for its high-quality proteins and diagnostic products used in biological research and clinical diagnostics.
Bio-Techne Corporation (NASDAQ:TECH) partnered with Leica Biosystems to automate RNAscope™ COVID-19 probes on the BOND RX* platform for research use. This advancement enables researchers to enhance their COVID-19 research protocols, minimizing manual labor and turnaround time. RNAscope™ probes detect SARS-Cov-2 RNA and related sequences, facilitating quicker breakthroughs in vaccine and treatment research. Bio-Techne generated approximately $739 million in net sales in fiscal 2020 and holds a diverse portfolio in diagnostic and genomic products.
Bio-Techne Corporation (NASDAQ:TECH) has introduced the SARS-CoV-1/2 Spike RBD LlaMABody Recombinant Antibody, designed to block viral entry by targeting the SARS-CoV-2 spike receptor binding domain. This innovative product is the first in the new LlaMABody line and represents a significant advancement in recombinant antibody technology. Camelid antibodies, known for their smaller size and enhanced stability, offer advantages in research and therapeutic applications. Bio-Techne continues to strengthen its position in the biopharma sector by expanding its portfolio of tools for SARS-CoV-2 research.
Bio-Techne Corporation (NASDAQ:TECH) reported a 8% decline in fourth-quarter organic revenue at $175.8 million, with full-year organic growth of 4% to $738.7 million. GAAP EPS soared to $1.48 from $0.42 YoY, while adjusted EPS fell to $1.00 from $1.25. Full-year GAAP EPS reached $5.82, a significant rise from $2.47 last year. Despite challenges posed by COVID-19, they maintained strong operating cash flow, increasing 13% year-over-year. The company continues to innovate in COVID-19 testing and diagnostics, partnering with Kantaro Biosciences to increase testing capabilities.
Bio-Techne Corporation (NASDAQ: TECH) has declared a quarterly dividend of $0.32 per share for the quarter ending June 30, 2020. The dividend will be paid on August 28, 2020 to shareholders on record as of August 18, 2020. The company reported approximately $739 million in net sales for fiscal 2020 and continues to focus on providing innovative tools and bioactive reagents for life sciences.
Bio-Techne Corporation (NASDAQ:TECH) appointed Julie L. Bushman as an independent director effective July 31, 2020. The board now comprises ten directors, with nine being independent. Bushman, former Executive Vice President at 3M, has extensive experience in global operations, digital software, and CIO roles. Her addition aims to enhance Bio-Techne's global expansion and operational efficiencies.
FAQ
What is the current stock price of Bio-Techne (TECH)?
What is the market cap of Bio-Techne (TECH)?
What are the primary business segments of Bio-Techne Corporation?
How does Bio-Techne support scientific research?
What distinguishes Bio-Techne in a competitive market?
Who are the main customers of Bio-Techne Corporation?
How does Bio-Techne ensure product quality and reliability?
What role do strategic partnerships play for the company?
Can you describe the global presence of Bio-Techne?
